About this Research Topic
There are several problems in the cell gene manufacturing in the CAR cell therapy world. The viral manufacturing and risks associated with the production and stability tests are an issue. Another issue is the systemic immunological and neurological reactions and disease transmission associated with cells not being properly cultured and then screened. The complexity of developing an effective and valuable cell gene therapy platform is the most important goal of any cell and gene developer. Solutions are in defining better targets so better on target and off tumor effects. One solution is to decrease cell-associated toxicities and therefore tailor the signal binding domain based on the type of tumor. We will decrease the CAR immunogenicity by using humanized anti-murine-derived CARs and define a better CAR T-Cell therapy for better trafficking and infiltration in the tumor microenvironment. Furthermore, prevention of the antigen escape is one of the most challenging limitations of CAR T-cell therapy. Over 80% of relapse or refractory patients are in hematological cancer (CD19 and BCMA CAR T cell therapies). Based on these recent developments, this new cell and gene therapy strategy has tremendous potential to become one major key in defining more effective and safer therapies against cancer.
The scope of this topic is to explore the state of the art of the cell gene therapy field and define the major limitations in the viral delivery and cell engineering. Furthermore, we will explore alternative pathways for manufacturing and treatment at scale in the autologous and allogenic settings.
This can be any type of manuscript from reviews to experimental papers.
Keywords: CAR-T therapy, Biomarker, Ag, Ab, target, allogeneic, autologous, cell therapy, virus, innate and adoptive cell therapy
Important Note: All contributions to this Research Topic must be within the scope of the section and journal to which they are submitted, as defined in their mission statements. Frontiers reserves the right to guide an out-of-scope manuscript to a more suitable section or journal at any stage of peer review.